TMDI VS HTGM Stock Comparison

Performance

TMDI
10/100

TMDI returned -73.08% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.10%, it's performance is below average giving it a grade of 10 of 100.

HTGM
10/100

HTGM returned -93.22% in the last 12 months. Based on SPY's performance of 2.57%, its performance is below average giving it a score of 10 of 100.

Sentiment

TMDI
65/100

TMDI had a bullish sentiment score of 64.63% across Twitter and StockTwits over the last 12 months. It had an average of 17.43 posts, 15.89 comments, and 57.00 likes per day.

HTGM

"Sentiment" not found for HTGM

Technicals

TMDI
14/100

TMDI receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

HTGM
14/100

HTGM receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

TMDI
16/100

TMDI has missed earnings 3 times in the last 20 quarters.

HTGM
10/100

HTGM has missed earnings 5 times in the last 20 quarters.

Volatility

TMDI
55/100

TMDI has had a higher than average amount of volatility over the last 12 months giving it a grade of 54 of 100.

HTGM
37/100

HTGM has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

Analyst Price Targets

TMDI

"Analyst Price Targets" not found for TMDI

HTGM
88/100

2 analysts offer 12-month price targets for HTGM. Together, they have an average target of 0.17, the most optimistic target put HTGM at 0.17 within 12-months and the most pessimistic has HTGM at 0.17. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Profit

TMDI

"Profit" not found for TMDI

HTGM
10/100

Out of the last 20 quarters, HTGM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Titan Medical Inc. Ordinary Shares Summary

Nasdaq / TMDI

Healthcare

Medical Devices

Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.

HTG Molecular Diagnostics, Inc. Common Stock Summary

Nasdaq / HTGM

Healthcare

Diagnostics & Research

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Power up your portfolio